Q9985 – Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ9985
- Long description
- Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- Short description
- Inj hydroxyprogst capoat nos
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Cross reference
- J1729
- Added
- July 1, 2017
- Last change
- January 1, 2018 – No change
- Termination date
- December 31, 2017
Frequently asked questions
What is HCPCS code Q9985?
Q9985 is a HCPCS Level II code for injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg. It was discontinued on December 31, 2017.
Does Medicare cover Q9985?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q9977 – Compounded drug, not otherwise classified
- Q9978 – Netupitant 300 mg and palonosetron 0.5 mg
- Q9979 – Injection, alemtuzumab, 1 mg
- Q9980 – Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg
- Q9981 – Rolapitant, oral, 1 mg
- Q9982 – Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries
- Q9983 – Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
- Q9984 – Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg
- Q9986 – Injection, hydroxyprogesterone caproate, (makena), 10 mg
- Q9987 – Pathogen(s) test for platelets
- Q9988 – Platelets, pheresis, pathogen-reduced, each unit
- Q9989 – Ustekinumab, for intravenous injection, 1 mg
- Q9991 – Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
- Q9992 – Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- Q9993 – Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- Q9994 – In-line cartridge containing digestive enzyme(s) for enteral feeding, each
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.